特瑞普利单抗在膀胱肿瘤综合治疗中的疗效和安全性分析

Analysis of the efficacy and safety of toripalimab in the comprehensive treatment of bladder tumors

摘要

目的 评价真实世界中特瑞普利单抗在膀胱尿路上皮癌（bladder urothelial carcinoma，UBC）及特殊类型膀胱肿瘤（atypical bladder tumor，ABT）综合治疗中的疗效及相关安全性。 方法 纳入46例手术+特瑞普利单抗综合治疗的膀胱肿瘤患者（32例尿路上皮癌、14例特殊类型肿瘤）的资料，统计分析治疗期间出现的治疗相关不良反应发生率及疗效评估。 结果 分组：尿路上皮癌患者32例，特殊类型膀胱肿瘤14例，在使用特瑞普利单抗的综合治疗中患者整体复发率为15.2%，46例患者常见不良反应包括皮肤瘙痒（17.4%），甲状腺功能异常（15.2%），食欲下降（10.9%）等，其中3～4级不良反应发生有14例，占总不良反应的36.8%。 结论 特瑞普利单抗在UBC和ABT的综合治疗中的疗效显著，整体安全可控，但应警惕不良反应。

Abstract

Objective To evaluate the efficacy and safety of toripalimab in the comprehensive treatment of bladder urothelial carcinoma（UBC） and atypical bladder tumor（ABT） in real-world settings. Methods Data from 46 patients with bladder tumors（32 with UBC and 14 with ABT） who underwent surgery combined with toripalimab treatment were included for analysis of occurrence rates of treatment-related adverse reactions and efficacy during the treatment period. Results For the 32 patients with UBC and 14 patients with ABT，the overall recurrence rate was 15.2% after the comprehensive treatment with toripalimab. Common adverse reactions observed in the 46 patients included pruritus（17.4%），thyroid dysfunction（15.2%），and decreased appetite（10.9%）. There were 14 events of grade 3-4 adverse reactions，accounting for 36.8% of the total adverse events. Conclusion Toripalimab demonstrates significant efficacy and overall manageable safety in the comprehensive treatment of UBC and ABT. However，vigilance is necessary for adverse reactions.

关键词

特瑞普利单抗 / 综合治疗 / 膀胱尿路上皮癌 / 特殊类型膀胱肿瘤 / 不良反应

Key words

toripalimab / comprehensive treatment / bladder urothelial carcinoma / special types of bladder tumor / adverse reaction